Schedule 13G ownership disclosure

INTERCEPT PHARMACEUTICALS IN

Security class unavailable · CUSIP: 45845P108

Event date: Unavailable

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
2,071,222
Percent of class
4.9500%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-23-108028
Form type
SC 13G/A
Filer
INTERCEPT PHARMACEUTICALS, INC.
CIK
CIK 1270073
Filed
Oct 10, 2023
Reporting period
—
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub